Platelets News and Research

RSS

Soliris (Eculizumab) granted orphan drug designation in Europe and U.S. for atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.

6 Aug 2009

FDA approves Effient (prasugrel) for heart attack in angioplasty patients

The U.S. Food and Drug Administration has approved the blood-thinning drug Effient tablets (prasugrel) to reduce the risk of blood clots from forming in patients who undergo angioplasty, a common procedure to unblock a clogged coronary artery.

12 Jul 2009

Genetic variations may contribute to depression in heart disease patients

Individuals with heart disease are twice as likely to suffer from depression as the general population, an association the medical community has largely been unable to explain.

19 May 2009

Discovery of molecule that could improve success of blood stem cell transplants

University of British Columbia researchers have discovered a "molecular key" that could help increase the success of blood stem cell transplants, a procedure currently used to treat diseases such as leukemia, Hodgkin's lymphoma and aplastic anemia.

22 Apr 2009

Research may lead to new ways to fight clot formation

When plaques coating blood vessel walls rupture and expose collagen, platelets spring into action to form a blood clot at the damaged site.

16 Apr 2009

Anti-clotting medications may be associated with brain microbleeds in older adults

Individuals who take aspirin or other medications that prevent blood clotting by inhibiting the accumulation of platelets appear more likely to have tiny, asymptomatic areas of bleeding in the brain, according to a report posted online today that will appear in the June print issue of Archives of Neurology.

13 Apr 2009

Varicella zoster infection causes severe autoimmune hepatitis

Autoimmune hepatitis (AIH) is a chronic liver inflammation of unknown etiology that is characterized by the presence of circulatory autoantibodies and ongoing liver tissue damage.

2 Apr 2009

Transdermal delivery of estrogen therapy may show safety benefits as opposed to oral delivery

Transdermal delivery of estrogen therapy available by prescription "seems not to alter" the risk of venous thromboembolism (VTE), or blood clotting, in postmenopausal patients when compared to oral delivery, a new study suggests.

29 Mar 2009

Injected luminol glows blue revealing immune cells' misdeeds

Detectives on television shows often spray crime scenes with a compound called luminol to make blood glow.

22 Mar 2009

Susceptibility to blood disorders may be inherited

Researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) have shown for the first time that a tendency to develop some blood disorders may be inherited.

15 Mar 2009

Schering-Plough's investigational oral thrombin receptor antagonist meets primary endpoint in a newly published study

Results of a Schering-Plough Corporation Phase II trial of SCH 530348, a novel oral thrombin receptor antagonist (TRA), were published today in The Lancet and demonstrated that the investigational antiplatelet compound met its primary endpoints of safety and tolerability.

12 Mar 2009

New drug derived from magnolia trees proves safe, tolerable in preventing blood clots

A new drug derived from magnolia trees appears to be able to uncouple two important functions of thrombin in blood clot formation and may offer a way to better control the potentially dangerous complications of bleeding and clot formation during procedures to open blocked coronary arteries, say researchers at the Duke Clinical Research Institute (DCRI).

12 Mar 2009

European Commission and US FDA approve intravenous formulation of temozolomide

Schering-Plough Corporation (NYSE:SGP) today announced that the European Commission and the US FDA both approved the intravenous (IV) formulation of temozolomide as an alternative to the already approved oral form of the drug.

5 Mar 2009

ViroPharma reports results of trial for Maribavir in bone marrow transplant patients

ViroPharma Incorporated has announced that its Phase 3 trial evaluating maribavir used as prophylaxis in allogeneic stem cell, or bone marrow, transplant (SCT) patients did not achieve its primary endpoint.

10 Feb 2009

Blood clotting cells help fight malaria

Australian researchers have discovered that blood clotting cells help fight malaria.

10 Feb 2009

Dengue outbreaks blamed for depletion of donated blood supply

The Red Cross in Queensland has issued an urgent call for blood donors to come forward as the collection of blood has been restricted in Dengue-affected areas.

19 Jan 2009

New clot-buster found

Exciting research into blood clotting by British Heart Foundation (BHF) researchers working at the University of Bristol will take us a step closer to better heart attack prevention and treatment.

19 Jan 2009

Portola Pharmaceuticals starts phase 2 trial of P2Y12 ADP receptor antagonist in non-urgent percutaneous coronary intervention

Portola Pharmaceuticals has announced that it has initiated patient enrollment in INNOVATE-PCI, a large Phase II clinical trial of PRT060128, the Company's novel P2Y12 ADP receptor antagonist, in patients undergoing non-urgent percutaneous coronary intervention (PCI).

10 Dec 2008

Older patients with acute myloid leukemia patients show promising response in drug study

Older patients with acute myloid leukemia (AML) who were once told that nothing could be done for them are finding new hope - and life - through a clinical trial at The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.

8 Dec 2008

Lenalidomide safe for elderly patients with chronic lymphocytic leukemia

The oral medication lenalidomide is safe and well-tolerated for elderly patients with chronic lymphocytic leukemia, a group without a well-defined frontline therapy for their disease, researchers from The University of Texas M. D. Anderson Cancer Center reported today at the 50th annual meeting of the American Society of Hematology.